WO2025004002 - TREATMENT OF POMPE DISEASE
National phase entry is expected:
Publication Number
WO/2025/004002
Publication Date
02.01.2025
International Application No.
PCT/IB2024/056362
International Filing Date
28.06.2024
Title **
[English]
TREATMENT OF POMPE DISEASE
[French]
TRAITEMENT DE LA MALADIE DE POMPE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
1-1, Doshomachi 4-chome
Chuo-ku
Osaka-shi, Osaka 541-0045, JP
Inventors
BOYANAPALLI, Ruby
c/o Takeda Development Center Americas, Inc.
500 Kendall Street
Cambridge, Massachusetts 02142, US
MOORE, Simon
c/o Takeda Development Center Americas, Inc.
500 Kendall Street
Cambridge, Massachusetts 02142, US
Priority Data
63/511,367
30.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 6281 | |
| EPO | Filing, Examination | 109943 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 38260 |
Total: 155648 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Variant acid alpha-glucosidase (GAA) polypeptides, codon-optimized polynucleotides encoding GAA, and GAA gene therapy methods and constructs are provided.[French]
L'invention concerne des polypeptides d'alpha-glucosidase acide (GAA) variants, des polynucléotides optimisés par codons codant pour GAA, ainsi que des méthodes et des constructions de thérapie génique à GAA.